Simcere isn’t one of the group of pre-revenue biotechs taking advantage of Hong Kong’s 2-year-old new rules that opened up the stock exchange. Read more: https://bit.ly/37q4NmO
© 2024 尹思哲 — Powered by WordPress
Theme by Anders Noren — Up ↑